glp-1 drug boom The weight loss is just getting started: What's next This gentle The GLP-1 drug boom has

After exploring a number of new molecules, Thornberry and her colleagues hit upon sitagliptin

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services

Trial of lixisenatide in early Parkinsons disease

Currently, a number of drugs have been launched worldwide, which not only benefit type 2 diabetes patients, but also bring hope to many obesity patients

Pulmonary aspiration, although rare, is a high-risk and potentially fatal complication

The analysis of 4887 participants treated with tirzepatide and 2,328 participants in the control groups identified 142 participants who developed at least one MACE-4p (inclusive of cardiovascular mortality, myocardial infarction, stroke, and hospitalization for unstable angina) and confirmed the cardiovascular safety with an hazard ratio (HR) of 0.80 (95% CI 0.571.11) for the comparison between tirzepatide and controls